Baqsimi is under clinical development by Amphastar Pharmaceuticals and currently in Phase III for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase III drugs for Type 1 Diabetes (Juvenile Diabetes) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Baqsimi’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Glucagon (Baqsimi) is an anti hypoglycemic agent. It is formulated as dry powder for inhalational route of administration (DPI). Baqsimi is indicated for the treatment of severe hypoglycemia in patients with diabetes ages 4 years and above.
Glucagon (LY-900018, AMG-5041) is under development for the treatment of severe hypoglycemia in type 1 and type 2 diabetes patients. The drug candidate is administered through intranasal route. It acts by targeting the glucagon receptor. The drug candidate is a new biological entity (NBE). It was also under development for the treatment of common cold.
Amphastar Pharmaceuticals overview
Amphastar Pharmaceuticals (Amphastar), is a specialty pharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, intranasal and inhalation products. It sells insulin-active pharmaceutical ingredient products. The company’s key products include enoxaparin sodium injection; cosyntropin for injection; naloxone hydrochloride (HCl) injection and phytonadione injection; lidocaine jelly; amphadase hyaluronidase injection; epinephrine, naloxone, phytonadione, primatene mist and glucagon. Amphastar offers its products to alternate care sites, hospitals, clinics and doctors’ offices and long-term care facilities. The company markets its products through subsidiaries, specialty distributors, wholesalers and retailers in the US, the UK, France and China. Amphastar is headquartered in Rancho Cucamonga, California, the US.
For a complete picture of Baqsimi’s drug-specific PTSR and LoA scores, buy the report here.